Cargando…
Fosfomycin, Applying Known Methods and Remedies to A New Era
The exponential increase in the numbers of isolates of Carbapenem-Resistant Enterobacteriaceae (CRE) creates the need for using novel therapeutic approaches to save the lives of patients. Fosfomycin has long been considered a rational option for the treatment of CRE to be used as part of a combined...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564589/ https://www.ncbi.nlm.nih.gov/pubmed/32784746 http://dx.doi.org/10.3390/diseases8030031 |
_version_ | 1783595749291851776 |
---|---|
author | M., Viviana Albán Mariño-Brito, Estefanía Villavicencio, Fernando Satán, Carolina Villacís, José E. Gestal, Mónica C. |
author_facet | M., Viviana Albán Mariño-Brito, Estefanía Villavicencio, Fernando Satán, Carolina Villacís, José E. Gestal, Mónica C. |
author_sort | M., Viviana Albán |
collection | PubMed |
description | The exponential increase in the numbers of isolates of Carbapenem-Resistant Enterobacteriaceae (CRE) creates the need for using novel therapeutic approaches to save the lives of patients. Fosfomycin has long been considered a rational option for the treatment of CRE to be used as part of a combined therapy scheme. However, the assessment of fosfomycin susceptibility in the laboratory presents a great challenge due to the discrepancies found between different methodologies. Thus, our goal was to evaluate fosfomycin susceptibility in a group of 150 Enterobacteriaceae bacterial isolates using agar dilution as the gold standard technique to compare the results with those obtained by disk diffusion. We found a fosfomycin susceptibility of 79.3% in general terms. By comparing both methodologies, we reported a categorical agreement of 96% without Very Major Errors (VMEs) or Major Errors (MEs) and 4% of minor Errors (mEs). Our results suggest that fosfomycin could provide a rational alternative treatment for those patients that are infected by a Multidrug-Resistant (MDR) microorganism that is currently untreatable and that the disk diffusion and classical agar dilution techniques are adequate to assess the resistance profile of CRE to fosfomycin. |
format | Online Article Text |
id | pubmed-7564589 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75645892020-10-29 Fosfomycin, Applying Known Methods and Remedies to A New Era M., Viviana Albán Mariño-Brito, Estefanía Villavicencio, Fernando Satán, Carolina Villacís, José E. Gestal, Mónica C. Diseases Article The exponential increase in the numbers of isolates of Carbapenem-Resistant Enterobacteriaceae (CRE) creates the need for using novel therapeutic approaches to save the lives of patients. Fosfomycin has long been considered a rational option for the treatment of CRE to be used as part of a combined therapy scheme. However, the assessment of fosfomycin susceptibility in the laboratory presents a great challenge due to the discrepancies found between different methodologies. Thus, our goal was to evaluate fosfomycin susceptibility in a group of 150 Enterobacteriaceae bacterial isolates using agar dilution as the gold standard technique to compare the results with those obtained by disk diffusion. We found a fosfomycin susceptibility of 79.3% in general terms. By comparing both methodologies, we reported a categorical agreement of 96% without Very Major Errors (VMEs) or Major Errors (MEs) and 4% of minor Errors (mEs). Our results suggest that fosfomycin could provide a rational alternative treatment for those patients that are infected by a Multidrug-Resistant (MDR) microorganism that is currently untreatable and that the disk diffusion and classical agar dilution techniques are adequate to assess the resistance profile of CRE to fosfomycin. MDPI 2020-08-07 /pmc/articles/PMC7564589/ /pubmed/32784746 http://dx.doi.org/10.3390/diseases8030031 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article M., Viviana Albán Mariño-Brito, Estefanía Villavicencio, Fernando Satán, Carolina Villacís, José E. Gestal, Mónica C. Fosfomycin, Applying Known Methods and Remedies to A New Era |
title | Fosfomycin, Applying Known Methods and Remedies to A New Era |
title_full | Fosfomycin, Applying Known Methods and Remedies to A New Era |
title_fullStr | Fosfomycin, Applying Known Methods and Remedies to A New Era |
title_full_unstemmed | Fosfomycin, Applying Known Methods and Remedies to A New Era |
title_short | Fosfomycin, Applying Known Methods and Remedies to A New Era |
title_sort | fosfomycin, applying known methods and remedies to a new era |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564589/ https://www.ncbi.nlm.nih.gov/pubmed/32784746 http://dx.doi.org/10.3390/diseases8030031 |
work_keys_str_mv | AT mvivianaalban fosfomycinapplyingknownmethodsandremediestoanewera AT marinobritoestefania fosfomycinapplyingknownmethodsandremediestoanewera AT villavicenciofernando fosfomycinapplyingknownmethodsandremediestoanewera AT satancarolina fosfomycinapplyingknownmethodsandremediestoanewera AT villacisjosee fosfomycinapplyingknownmethodsandremediestoanewera AT gestalmonicac fosfomycinapplyingknownmethodsandremediestoanewera |